China
Wins in court have been key to the six-year-old firm’s growth, as one of its founders explains
Loke Khoon Tan and Stephanie Yip at Dentons explain what brand owners need to know ahead of January 1 2027, when updates to China’s Trade Mark Law come into force
New US bills signal that firms should work with clients to ensure they are complying with potential regulatory requirements
Nick Redfearn, head of enforcement at Rouse and a classic car enthusiast, explains the sudden viral appearance of classic car restomod parts from China and the impact of IP in this new trade
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry -
Sponsored by Liu Shen & AssociatesRan Wang of Liu, Shen & Associates outlines the guidance the cited cases offer on issues such as patent evaluation reports, infringement judgments after invalidation, use environment features, and amendment rules
-
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
-
Sponsored by Liu Shen & AssociatesGuanyang Yao of Liu, Shen & Associates reviews several Chinese court rulings on standard-essential patent disputes, including Panasonic v Oppo, and the growing judicial focus on mediation and comparable licences over top-down rate setting
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations involving active ingredients that are chemically reactive
-
Sponsored by Wanhuida Intellectual PropertyHonghui Hu of Wanhuida Intellectual Property examines how the Supreme People’s Court has clarified the patent scope of drug combination inventions in a patent linkage dispute, offering rare guidance on claim interpretation of pharmaceutical combinations
